Equities

Profile data is unavailable for this security.

About the company

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology, rare diseases and consumer healthcare. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. Its brands include Prevnar 13, Xeljanz, Eliquis, Lipitor, Celebrex, Pristiq and Viagra.

  • Revenue in USD (TTM)53.04bn
  • Net income in USD15.42bn
  • Incorporated1942
  • Employees92.40k
  • Location
    Pfizer Inc235 E 42ND STNEW YORK 10017-5703United StatesUSA
  • Phone+1 (212) 573-2323
  • Fax+1 (302) 655-5049
  • Websitehttps://www.pfizer.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PFE:NYQ since
announced
Transaction
value
Array Biopharma IncDeal completed17 Jun 201917 Jun 2019Deal completed-13.54%11.37bn
Therachon AG (Now 4j8824)Deal completed08 May 201908 May 2019Deal completed-9.45%810.00m
Data delayed at least 15 minutes, as of Nov 12 2019 23:30 GMT.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.